Shots: The approval is based on a biomarker subgroup analysis of P-III PAOLA-1 study assessing Lynparza + bevacizumab vs bevacizumab alone as 1L maintenance treatment in patients with newly diagnosed advanced […]readmore
Tags : Ovarian
Shots: The approval is based on PRIMA study assessing Zejula (300mg qd), later amended to incorporate an individualised starting dose of Zejula (200 mg or 300 mg, qd) based on […]readmore
Shots: The P-III PRIMA study involves assessing of Zejula (200 mg, qd) vs PBO as 1L maintenance therapy in patients in a ratio (2:1) with stage III or IV ovarian […]readmore
Shots: GSK to acquire Tesaro, in all stock transaction with its Zejula and preclinical candidates. Tesaro to get $75/share in cash for a premium of 62% with total deal value […]readmore